Taysha Gene Therapies is a biotechnology business based in the US. Taysha Gene Therapies shares (TSHA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.01 – a decrease of 11.45% over the previous week. Taysha Gene Therapies employs 52 staff and has a trailing 12-month revenue of around $9.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.01 |
|---|---|
| 52-week range | $1.19 - $4.32 |
| 50-day moving average | $1.98 |
| 200-day moving average | $2.39 |
| Wall St. target price | $6.41 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.50 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.12 from 2024-11-19
| 1 week (2024-11-15) | 2.91% |
|---|---|
| 1 month (2024-10-22) | 6.53% |
| 3 months (2024-08-22) | -5.36% |
| 6 months (2024-05-22) | -28.62% |
| 1 year (2023-11-22) | 15.22% |
|---|---|
| 2 years (2022-11-22) | -5.78% |
| 3 years (2021-11-22) | 11.78 |
| 5 years (2019-11-18) | N/A |
| Revenue TTM | $9.9 million |
|---|---|
| Gross profit TTM | $2.5 million |
| Return on assets TTM | -27.42% |
| Return on equity TTM | -114.77% |
| Profit margin | -229.67% |
| Book value | $0.33 |
| Market Capitalization | $465.2 million |
TTM: trailing 12 months
We're not expecting Taysha Gene Therapies to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Taysha Gene Therapies's shares have ranged in value from as little as $1.19 up to $4.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Taysha Gene Therapies's is 0.414. This would suggest that Taysha Gene Therapies's shares are less volatile than average (for this exchange).
To put Taysha Gene Therapies's beta into context you can compare it against those of similar companies.
Taysha Gene Therapies, Inc. , a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.